RT  - European Journal of Gynaecological Oncology
ID  - 10.12892/ejgo4848.2019
T1  - Role of nesfatin in endometrial cancers
A1  - M. Szarszewska
A1  - J. Markowska
A1  - A. Gryboś
A1  - A. Marszalek
A1  - V. Filas
A1  - J. Żurawski
A1  - M. Jóźwik
A1  - A. Olejek
A1  - W. Bednarek
A1  - R. Mądry
A1  - R. Jach
A1  - A. Markowska
K1  - Enodmetrial cancer; Nesfatin; Molecular factors
YR  - 2019
SP  - 825
AB  - <p><i>Aims:</i> Endometrial cancers (ECs) represent a heterogeneous group of cancers with different types of histology, etiology, and prognosis. The largest risk factors for EC are obesity and diabetes. Nesfatin regulates food intake and glucose homeostasis. The aim of this multicentre study was closer recognition of nesfatin and other molecular factors in ECs. <i>Materials and Methods:</i> Using sections of paraffinembedded preparations and immunohistochemistry, the expression of nesfatin (NESF 1), estrogen receptors (ER α and β1), and progesterone receptor (PR) was examined in 146 cancer patients (115 EC type I and 33 type II). <i>Results:</i> In EC type I, a higher expression of PR, but lower ER β1 was found. No significant difference was detected in NESF 1 and ER α expression between the two types of ECs. ER α expression was higher in early stages of EC, and in more advanced cases ER β1 staining was weaker. In EC types I and II, a high expression of NESF 1 correlated with a high expression of ER α. Lower nesfatin expression correlated with low cells differentiation (grading) in EC type I. A tendency towards high expression of nesfatin was noted in patients with a lack of ER β1 expression. No correlation was found between the expression of NESF 1 and PR in any of the groups. <i>Conclusions: </i>The role of nesfatin in EC is still poorly understood. In EC type I, a high expression of NESF 1 seems to represent a favourable prognostic factor, while in type II its role is still unknown.</p>